J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harty, L.
Right arrow Articles by Power, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harty, L.
Right arrow Articles by Power, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

FORUM

Race and Ethnicity in the Era of Emerging Pharmacogenomics

Lea Harty, PhD, Keith Johnson, PhD and Aidan Power, MB, BCh, MRCPsych

From Clinical Research and Development, Pfizer Global Research and Development, New London, Connecticut (Dr Harty and Dr Power) and Clinical Research and Development, Pfizer Global Research and Development, Ann Arbor, Michigan (Dr Johnson).

Race and ethnicity are terms that are commonly used to categorize subjects in medical research. Advances in genetics and the emerging discipline of pharmacogenomics have brought these terms under scrutiny, with arguments either for the continued use or for the abandonment of these terms generating strong views. As pharmacogenomics research develops, we may find that more accurate and specific descriptions of relevant variation in genes will reduce the value that these imprecise descriptors have in predicting how people will respond to drug therapies.


Key Words: Pharmacogenomicsraceethnicitygenetics

Address for reprints: Aidan Power, MB, BCh, MRCPsych, Pfizer Global Research and Development, 50 Pequot Avenue, New London, CT 06320; e-mail: aidan.c.power{at}pfizer.com.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Journal of Health Politics, Policy and LawHome page
V. L. Bonham, T. Citrin, S. M. Modell, T. H. Franklin, E. W. B. Bleicher, and L. M. Fleck
Community-Based Dialogue: Engaging Communities of Color in the United States' Genetics Policy Conversation
Journal of Health Politics Policy and Law, June 1, 2009; 34(3): 325 - 359.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
R. Temple and N. L. Stockbridge
BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective
Ann Intern Med, January 2, 2007; 146(1): 57 - 62.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Clinical Pharmacology